Vaccine Development
Developing a vaccine against several diseases remains a challenge. Vaccine Research & Development is very complex and costly because a vaccine is a biological product that is made from the living microorganisms. Therefore, its development cycle is quite different from the other pharmaceutical products. There are so many microbes that can cause disease, and the goal for a vaccine is to protect against all of them. There is limited understanding of how severe disease occurs and how the microbes interacts with the immune system. Several vaccine candidates are in clinical stages of development. The pre-clinical development stage is the first step to identify a vaccine candidate that determines a vaccine’s ultimate safety profile. Phase I trials is the stage where the researchers test the candidate vaccine for the first time in humans to evaluate its safety, safe dosage range, and vaccine-related side effects. Phase II trials is the stage where the candidate vaccine is administered to a larger group of people for the evaluation of its immunogenicity and safety. The goal of phase III is to conduct a large-scale safety and efficacy study on a relevant patient population. It is really very complex to market a new vaccine and once it has been marketed, pharmacovigilance activities take place in order to conduct a strict safety supervision of that vaccine.
- Product Development for Vaccines
- HIV Vaccine Research
- Approaches to Mucosal-Vaccines
- Global Vaccine
- Surveillance, Assessment and Monitoring
- Meningitis Vaccine Project (MVP)
- Pre-Clinical and Clinical Development
- Polymeric Nanoparticle Delivery
Related Conference of Vaccine Development
9th International Conference on Vaccines, Immunology and Clinical Trials
7th International conference on Vaccines, Vaccination and Immunization
Vaccine Development Conference Speakers
Recommended Sessions
- Advances in Vaccine Technology
- Biomarkers of Vaccine Adjuvant Potency and Safety
- Human Genetics and Vaccines
- Immunology / Animal Models
- Nanotechnology in Vaccine Delivery System
- Novel Vaccines Against Infectious Diseases
- Vaccine Adjuvants
- Vaccine Adjuvants- FDA & CDC
- Vaccine Delivery
- Vaccine Design, Production and Safety
- Vaccine Development
- Vaccine Safety Monitoring
- Vaccines Adjuvants Market Analysis
- Vaccines Against Infectious Diseases and Cancer
- Veterinary Vaccines and Their Delivery Systems
Related Journals
Are you interested in
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Animal & Plant Derived Vaccines - Vaccines-Immunization-2026 (France)
- Animal Models & Clinical Trials - Vaccines-Immunization-2026 (France)
- Antibodies: Engineering & Therapeutics - Vaccines-Immunization-2026 (France)
- Cancer, Malaria & TB Vaccines - Vaccines-Immunization-2026 (France)
- Cellular Immunology & Latest Innovations - Vaccines-Immunization-2026 (France)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Combination & Conjugate Vaccines - Vaccines-Immunization-2026 (France)
- Current Research & Future Challenges - Vaccines-Immunization-2026 (France)
- DNA & Synthetic Vaccines - Vaccines-Immunization-2026 (France)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fish & Poultry Vaccines - Vaccines-Immunization-2026 (France)
- Geriatric Immunization - Vaccines-Immunization-2026 (France)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- HIV Vaccines - Vaccines-Immunization-2026 (France)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Paediatric Vaccination - Vaccines-Immunization-2026 (France)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Travel & Edible Vaccines - Vaccines-Immunization-2026 (France)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine Production & Development - Vaccines-Immunization-2026 (France)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccines - Vaccines-Immunization-2026 (France)
- Vaccines & Autism - Vaccines-Immunization-2026 (France)
- Vaccines against Drugs - Vaccines-Immunization-2026 (France)
- Vaccines against Infectious Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Immune Mediated Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Pregnant Women & Neonates - Vaccines-Immunization-2026 (France)
- Vaccines for Unconventional Diseases - Vaccines-Immunization-2026 (France)
- Vectors, Adjuvants & Delivery Systems - Vaccines-Immunization-2026 (France)
